PCM
BIOTW

Prelude Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Prelude Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,731
Closed -$1K – 1794
2022
Q3 		$1K Buy
+18,731
New +$1.09K ﹤0.01% 1508
2022
Q1 		– Sell
-18,154
Closed -$12K – 2439
2021
Q4 		$12K Buy
18,154
+2,150
+13% +$1.49K ﹤0.01% 1871
2021
Q3 		$11K Hold
16,004
– – ﹤0.01% 1629
2021
Q2 		$14K Buy
+16,004
New +$11.1K ﹤0.01% 1568

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Prelude Capital Management's BIOTW Position: Q4 2022 in Review

Prelude Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q4 2022, closing a stake of 18,731 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in BIOTW in Q2 2021 and held it in 4 quarters. The position peaked at $14K in Q2 2021. 48 funds tracked by Wall St. Rank hold BIOTW as of Q4 2022.

  • Prelude Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 18,731 Biotech Acquisition Company Warrant shares in Q4 2022, an estimated $1K.
  • Prelude Capital Management first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 4 quarters.
  • Prelude Capital Management's Biotech Acquisition Company Warrant position peaked at $14K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.